Loading
A phase 3 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT06973187 by BeOne Medicines, with 500 participants planned, started 2025-09-04 and due to reach its primary completion in 2028-04-17. Interventions recorded: Tacabrutideg and Pirtobrutinib.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.